did anyone notice?

..... that when the Southern Cross Equities report came out, that management didn't announce this? To me, this must mean that coverage was initiated by SCE and not one of those paid for analysts reports that we see so many companies putting out, I checked SCE's disclosure and they make no mention of a paid report, most companies that seek a report to get the word out will firstly pay for it and secondly announce it to the world!!

Real deal to me, can't wait, really I can't wait!!!

Target price $2.00

We value Alchemia on a probability-weighted DCF basis at $1.98 base case
and $3.28 optimistic case. Our $2.00 price target sits at the low point of this
range. We anticipate Alchemia being re-rated by the market once FDA
approval of fondaparinux is granted, and a Phase III trial of Alchemia?s HA-Irinotecan cancer drug formulation gets underway.

Gluck all.....